Live Breaking News & Updates on Taly And Spain To Increase Screening Identification Of Cancer Patients With Nrg1 Fusion Tumors Raise Awareness The Phase 1 2 Enrgy Clinical Trial

Published: May 13, 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
® and Triclonics
®), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno). In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions. Each collaborating organization in turn has agreed as follows: ....

United States , United Kingdom , Zenocutuzumab Zeno , Andrew Joe , Michele Reni , Kathleen Farren , Exchange Commission , San Raffaele Scientific Institute , Communications Specialist , Italian Association For The Study Of Pancreas , Principal Investigator , Universidad De Navarra , Chief Medical Officer , North America , Merus Dock , Zeno Dock , Private Securities Litigation Reform Act , Quarterly Report , Media Inquiries , Erus Announces Collaborations In Israel , Taly And Spain To Increase Screening Identification Of Cancer Patients With Nrg1 Fusion Tumors Raise Awareness The Phase 1 2 Enrgy Clinical Trial , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஆண்ட்ரூ ஓஹோ , க்யாத்லீந் ஃப்யாரந் , பரிமாற்றம் தரகு ,